Jack D. Sobel, MD

Michael L. Krychman, MD, and Jack D. Sobel, MD, discuss the importance of awareness and education about RVVC, particularly given the impact of symptoms on patients’ psychosocial and sexual behavior.

Michael L. Krychman, MD, and Jack D. Sobel, MD, discuss the practical challenges of access to newer, FDA-approved medications for RVVC and how the third-party reimbursement landscape may take shape in coming years.

Experts explore the availability and cost as well as other unanswered questions regarding emerging agents for the treatment of RVVC.

Michael L. Krychman, MD, and Jack D. Sobel, MD, review the mechanisms of ibrexafungerp and how it might fit in the treatment spectrum for RVVC.

Michael L. Krychman, MD, and Jack D. Sobel, MD, review the clinical implications of the recent approval of oteseconazole, which has been shown to be efficacious and well tolerated in RVVC treatment.

Thought leaders discuss the history of RVVC treatment, including the use of unapproved topical antifungals and the shortcomings of fluconazole.

Michael L. Krychman, MD, and Jack D. Sobel, MD, explore avenues for confirming a diagnosis of RVVC, including cultures and molecular testing.

Michael L. Krychman, MD, and Jack D. Sobel, MD, review diagnostic criteria of diagnosis of RVVC and the impact of misdiagnosis.

Michael L. Krychman, MD and Jack D. Sobel, MD, talk about the signs and symptoms of vulvovaginal candidiasis as well as its effect on patient quality of life.